Post traumatic stress disorder (PTSD) is a chronic and debilitating mental illness. Atypical antipsychotics are often utilized for treatment of PTSD despite the limited data. The purpose of this article is to review published clinical trials of atypical antipsychotics used in the treatment of PTSD. Certain patients may benefit from therapy with an atypical antipsychotic, particularly for those with hyper-arousal or re-experiencing symptom clusters. At this time, guidelines suggest against the use of risperidone as augmentation therapy in patients with PTSD. Data are only available for olanzapine, quetiapine, and aripiprazole; however, data were conflicting, not very robust, and studies had limited sample sizes and narrow demographics. It is important to provide proper patient education and weigh the risks versus benefits of therapy with an atypical antipsychotic as metabolic side effects are well documented.
CITATION STYLE
Connell, R., Zeier, K., & Thomas, C. J. (2013, January 1). A review of atypical antipsychotics and their utility in post-traumatic stress disorder. Mental Health Clinician. Allen Press Inc. https://doi.org/10.9740/mhc.n131049
Mendeley helps you to discover research relevant for your work.